Collaboration aims to harness Tevogen’s proprietary immunotherapy platform and Dr. Neal Flomenberg’s expertise in research and the transplantation of T cells
Company announces publication of DARE-BV1 proof-of-concept study for proprietary thermosetting hydrogel formulation of clindamycin phosphate for one-time vaginal administration
Encouraging preclinical results demonstrate a strong antibody and cellular immune response and 100-percent protection against SARS-CoV-2 infection following a single vaccination